Thu, September 30, 2010
Wed, September 29, 2010
Tue, September 28, 2010
Mon, September 27, 2010
[ Mon, Sep 27th 2010 ] - Market Wire
Wellstar Announces New Website
Sun, September 26, 2010
Sat, September 25, 2010
Fri, September 24, 2010
Thu, September 23, 2010
Wed, September 22, 2010
Tue, September 21, 2010
Mon, September 20, 2010
Fri, September 17, 2010
Thu, September 16, 2010
Wed, September 15, 2010
[ Wed, Sep 15th 2010 ] - Market Wire
Qtrax Beta Available in India
Tue, September 14, 2010
Mon, September 13, 2010
Sun, September 12, 2010
Fri, September 10, 2010
Thu, September 9, 2010

BioCryst to Present At JMP Securities Healthcare Conference


//health-fitness.news-articles.net/content/2010/ .. ent-at-jmp-securities-healthcare-conference.html
Published in Health and Fitness on Tuesday, September 21st 2010 at 4:00 GMT by Market Wire   Print publication without navigation


BIRMINGHAM, Ala.--([ BUSINESS WIRE ])--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer of BioCryst, plans to provide a corporate summary and updates regarding its clinical programs at the JMP Securities Healthcare Conference in New York City on Monday, September 27, 2010 at 2:30 p.m. Eastern Time.

Links to a live audio Web cast and replay of the presentation may be accessed on the BioCryst Web site at [ www.biocryst.com ].

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor forhematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at [ www.biocryst.com ].

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at [ http://investor.shareholder.com/biocryst/sec.cfm ].

BCRXW


Publication Contributing Sources